Zytiga

Castration, Prostatic Neoplasms, Malignant Neoplasms
Treatment
6 FDA approvals
20 Active Studies for Zytiga

What is Zytiga

AbirateroneThe Generic name of this drug
Treatment SummaryAbiraterone is a type of steroid hormone used to treat prostate cancer that does not respond to other treatments. It is available as an acetate salt, which is more easily absorbed by the body and less likely to be broken down. Abiraterone was approved by the FDA in 2011.
Zytigais the brand name
image of different drug pills on a surface
Zytiga Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Zytiga
Abiraterone
2011
43

Approved as Treatment by the FDA

Abiraterone, commonly known as Zytiga, is approved by the FDA for 6 uses such as Castration and Prostatic Neoplasms .
Castration
Used to treat Metastatic Castration Resistant Prostate Cancer (CRPC) in combination with Methylprednisolone
Prostatic Neoplasms
Used to treat High Risk Prostate Cancer in combination with Prednisone
Malignant Neoplasms
Used to treat Metastatic Castration Sensitive Prostate Cancer in combination with Prednisone
Metastatic Castration Resistant Prostate Cancer (CRPC)
Used to treat Metastatic Castration Resistant Prostate Cancer (CRPC) in combination with Methylprednisolone
High Risk Prostate Cancer
Used to treat High Risk Prostate Cancer in combination with Prednisone
Metastatic Castration Sensitive Prostate Cancer
Used to treat Metastatic Castration Sensitive Prostate Cancer in combination with Prednisone

Effectiveness

How Zytiga Affects PatientsAbiraterone is linked to decreases in PSA levels and tumor size, as well as lessening of bone metastases and pain relief. Taking this drug may cause an increase in hormones related to the adrenal glands, but this can be prevented by taking the steroid dexamethasone.
How Zytiga works in the bodyAbiraterone is a drug that works to lower the amount of testosterone in the body. It does this by blocking an enzyme called CYP17A1, which helps the body create testosterone. By blocking the enzyme, it prevents the body from producing testosterone and lowers the amount of testosterone in the body.

When to interrupt dosage

The suggested dosage of Zytiga is contingent upon the diagnosed health state. The dose varies, based on the administration approach outlined in the table beneath.
Condition
Dosage
Administration
Castration
250.0 mg, , 500.0 mg, 125.0 mg, 1000.0 mg
, Oral, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet
Prostatic Neoplasms
250.0 mg, , 500.0 mg, 125.0 mg, 1000.0 mg
, Oral, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet
Malignant Neoplasms
250.0 mg, , 500.0 mg, 125.0 mg, 1000.0 mg
, Oral, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet

Warnings

There are 20 known major drug interactions with Zytiga.
Common Zytiga Drug Interactions
Drug Name
Risk Level
Description
Brigatinib
Major
The metabolism of Brigatinib can be decreased when combined with Abiraterone.
Cabazitaxel
Major
The metabolism of Cabazitaxel can be decreased when combined with Abiraterone.
Eliglustat
Major
The metabolism of Eliglustat can be decreased when combined with Abiraterone.
Fentanyl
Major
The metabolism of Fentanyl can be decreased when combined with Abiraterone.
Paclitaxel
Major
The metabolism of Paclitaxel can be decreased when combined with Abiraterone.
Zytiga Toxicity & Overdose RiskOverdosing on this drug can cause a disruption of the body's 17α-hydroxylase activity, leading to high levels of a mineralocorticoid called 11-deoxycorticosterone. This can cause water retention and low potassium levels in the blood. To counteract these symptoms, mineralocorticoid receptor antagonists can be prescribed.
image of a doctor in a lab doing drug, clinical research

Zytiga Novel Uses: Which Conditions Have a Clinical Trial Featuring Zytiga?

30 ongoing clinical trials are investigating the potential of Zytiga to manage Castration-Resistant Prostate Cancer.
Condition
Clinical Trials
Trial Phases
Castration
31 Actively Recruiting
Phase 1, Phase 2, Phase 3
Prostatic Neoplasms
4 Actively Recruiting
Phase 2, Early Phase 1, Phase 1
Malignant Neoplasms
2 Actively Recruiting
Phase 3, Phase 1

Zytiga Reviews: What are patients saying about Zytiga?

5Patient Review
5/15/2013
Zytiga for Metastatic Castration-Resistant Prostate Cancer
Zytiga has been an absolute lifesaver for my husband. In just five months, his PSA levels have decreased from 1000 to 62 with no negative side effects that we've seen. This drug has given him back a quality of life that was rapidly deteriorating due to chemotherapy. We've been treating his stage 4 cancer for 11 years now, and this is by far the most promising treatment we've tried.
5Patient Review
7/24/2013
Zytiga for Metastatic Castration-Resistant Prostate Cancer
I started quarterly lupron injections at my doctor's suggestion. They worked for a while, but then my PSA started rising again. My doctor put me on Zytiga, and within the first month my PSA went from 135 to 3.5. Two months later it was down to 0.3. This medication has been a life-saver!
5Patient Review
7/24/2013
Zytiga for Metastatic Castration-Resistant Prostate Cancer
Lupron injections were initially effective for six months, but failed to address my continuing high PSA. My doctor then put me on Zytiga, and within the first 30 days my PSA went from 135 to 3.5. 60 days later it was down to 0.3.
5Patient Review
5/15/2013
Zytiga for Metastatic Castration-Resistant Prostate Cancer
Zytiga has been amazing for my husband. In only five months, it's brought his PSA levels down from over 1000 to 62. He hasn't experienced any negative side effects and it's given him back a much better quality of life. We're so grateful that this treatment option was available to us.
5Patient Review
9/27/2013
Zytiga for Metastatic Castration-Resistant Prostate Cancer
I have been taking this medication for two months with great success. My PSA levels dropped significantly, and I haven't experienced any negative side effects. The only downside is the cost--it can get pretty pricey.
5Patient Review
5/9/2014
Zytiga for Metastatic Castration-Resistant Prostate Cancer
I took Casodex and it worked for me for an entire year. I'm now on Zytiga and have been for about the same amount of time with great results; my PSA was at 500 when I started treatment two years ago, and now it's down to 0.01.
5Patient Review
10/20/2012
Zytiga for Metastatic Castration-Resistant Prostate Cancer
5Patient Review
9/27/2013
Zytiga for Metastatic Castration-Resistant Prostate Cancer
I've been taking this for two months with no negative consequences that I can see. My PSA went from 3.45 to 0.40, which is a dramatic improvement. The only downside is the cost; without insurance, this medication costs around $6-7000 per year.
5Patient Review
10/20/2012
Zytiga for Metastatic Castration-Resistant Prostate Cancer
5Patient Review
1/19/2015
Zytiga for Metastatic Castration-Resistant Prostate Cancer
My dad is currently 78 years old and was first diagnosed with Gleason 9 and PSA 32 back in 1996. Despite this, he still works full time and enjoys a great quality of life. He started taking Zytiga with prednisone in April 2014 when his PSA began to rise again, peaking at 214. However, since then his PSA has steadily decreased with very few side effects. Here are his latest numbers: May 2014 – PSA 125; June 2014 – PSA 26.6; July 2014 – PSA 24.3; August 2014 – PSA 18.8; October 2014 – PSA 16
5Patient Review
5/9/2014
Zytiga for Metastatic Castration-Resistant Prostate Cancer
Casodex worked for about a year for me. I'm now on Zytiga and it's been effective for another year. My PSA was at 500 when I started treatment two years ago, and it's now down to 0.01.
5Patient Review
1/19/2015
Zytiga for Metastatic Castration-Resistant Prostate Cancer
My dad is 78 and he was first diagnosed with cancer in 1996. He's still working full time and enjoying a great quality of life. In April 2014, his PSA started rising again, so he began treatment with Zytiga and prednisone. His PSA has been steadily decreasing since then with very few side effects.
4.7Patient Review
3/27/2013
Zytiga for Metastatic Castration-Resistant Prostate Cancer
I've been taking Zytiga for 19 months now and have found it to be incredibly effective. My PSA levels dropped immediately from 300 to 25 and they've stayed put since then. The only downside is that I developed a cough shortly after starting the medication, which has now become chronic.
4.7Patient Review
3/27/2013
Zytiga for Metastatic Castration-Resistant Prostate Cancer
I've been taking Zytiga for 19 months now and have found it to be effective; my PSA levels dropped from 300 to 25 almost immediately. However, I have developed a chronic cough since beginning treatment, which is apparently a common side effect according to the manufacturer's clinical trials.
4.7Patient Review
12/29/2013
Zytiga for Metastatic Castration-Resistant Prostate Cancer
This drug quickly and effectively lowered my PSA levels, from 22 to 0.013 in the span of a few months. I also receive Lupron shots every 3 months, which may account for some of the success.
4.7Patient Review
5/7/2014
Zytiga for Metastatic Castration-Resistant Prostate Cancer
My father's PSA levels have decreased significantly since he began taking Zytiga and prednisone 13 days ago. He feels great and we are attributing this change to the medication.
4.7Patient Review
8/9/2014
Zytiga for Metastatic Castration-Resistant Prostate Cancer
I started taking this drug on December 1st, 2013. My PSA was at 35.8. By March 1st, 2014, my PSA had dropped to 5.3 and I reduced my dosage to 750mg. Through June 1st, 2014, my PSA was at 3.0 and level. I am now continuing to monitor to date August 1st, 2014 with a PSA of 3.0 HC
4.7Patient Review
12/29/2013
Zytiga for Metastatic Castration-Resistant Prostate Cancer
This drug has been working great for me. When I started, my PSA was 22. Last check in Nov 2013, it was down to 0.013. In combination with Lupron shots every 3 months, this treatment has been really effective.
4.7Patient Review
5/7/2014
Zytiga for Metastatic Castration-Resistant Prostate Cancer
I am so pleased with how this treatment has worked for my father. In just 13 days, his PSA levels have dropped from 214 to 125. He's feeling great and we are attributing it all to the grace of God.
4.7Patient Review
8/9/2014
Zytiga for Metastatic Castration-Resistant Prostate Cancer
I began taking 1000mg of this drug on 12/1/2013 when my PSA was 35.8. By 3/1/2014, my PSA had reduced to 5.3, so I decreased the dosage to 750mg. As of 8/1/2014, my PSA is still at 3.0.
4.3Patient Review
10/27/2013
Zytiga for Metastatic Castration-Resistant Prostate Cancer
I was diagnosed in 1995 with a PSA of 83. I underwent radiation, Lupron, and casodex treatment which worked until recently when my PSA went from 9 to 19. After 3 weeks on Zytiga, my PSA is now back down to 9 with minimal side effects.
4.3Patient Review
11/25/2019
Zytiga for Metastatic Castration-Resistant Prostate Cancer
So far, this drug has been a miracle for me. My PSA level dropped from over 400 to just 7.2 in less than 2 months without any side effects. I'm participating in a clinical trial right now and I don't know what's going to happen when it's over. This medication has greatly improved the quality of my life in all areas.
4.3Patient Review
10/27/2013
Zytiga for Metastatic Castration-Resistant Prostate Cancer
After my initial diagnosis in 1995 and various treatments over the years, this is the first one that has worked with minimal side effects.
4.3Patient Review
11/25/2019
Zytiga for Metastatic Castration-Resistant Prostate Cancer
So far, this drug has been working really well for me. My PSA levels have dropped from 400 to 7.2 in less than two months, and I haven't experienced any negative side effects. I'm participating in a clinical trial right now, and I'm worried about what will happen when the study is over.
4Patient Review
1/31/2015
Zytiga for Metastatic Castration-Resistant Prostate Cancer
This treatment was highly effective for me. Within two months, my PSA dropped from 600 to 10 after taking Zytiga and Prednison. I experienced very few side effects, which was great.
4Patient Review
1/31/2015
Zytiga for Metastatic Castration-Resistant Prostate Cancer
Zytiga and Prednison really helped lower my PSA levels. I saw a difference within two months, and experienced few side effects.
4Patient Review
1/30/2017
Zytiga for Metastatic Castration-Resistant Prostate Cancer
After switching from Casodex to Zytiga, I saw a significant decrease in my PSA levels over the course of six months.
4Patient Review
1/30/2017
Zytiga for Metastatic Castration-Resistant Prostate Cancer
After I stopped using Casodex and started taking Zytiga, my PSA levels decreased significantly over the course of six months.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about zytiga

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

How long do you take Zytiga?

"Many people with prostate cancer must take Zytiga for 2-3 years, resulting in hundreds of thousands of dollars in treatment costs."

Answered by AI

How long can you survive Zytiga?

"Patients who took Zytiga had an average lifespan of 35.3 months, while those who took the placebo only lived for 30.1 months on average."

Answered by AI

What are the side effects of Zytiga?

"If you are feeling any of the following symptoms, you may be experiencing menopause: fatigue, joint pain, high blood pressure, nausea, leg or feet swelling, low blood potassium levels, hot flushes, diarrhea."

Answered by AI

What is the side effect of Zytiga?

"ZYTIGA® may cause some serious side effects. These include high blood pressure, low potassium levels in the blood, fluid retention, and irregular heartbeats."

Answered by AI

Is Zytiga a form of chemotherapy?

"Zytiga (abiraterone acetate) is used to treat men with metastasized prostate cancer, alongside prednisone. It is not a form of chemotherapy, despite being used to treat cancer."

Answered by AI

What does the drug Zytiga do?

"ZYTIGA is a prescription medication that is to be used in conjunction with prednisone. It is specifically meant to treat prostate cancer that has spread to other areas of the body in male patients."

Answered by AI

Clinical Trials for Zytiga

Image of BAMF Health in Grand Rapids, United States.

AB001 for Prostate Cancer

18+
Male
Grand Rapids, MI
This study is designed to investigate the safety, tolerability, and effectiveness of a new treatment called AB001 in both 177Lu-PSMA naïve and 177Lu-PSMA experienced patients with advanced prostate cancer. AB001 targets a specific protein found on prostate cancer cells called prostate specific membrane antigen (PSMA) and delivers radioactive particles to kill the cancer cells. The primary goal of the study is to determine the safety profile of AB001 and how well patients tolerate the treatment. Researchers also aim to identify the best dose and schedule for further testing and clinical development. AB001 could be a promising treatment because it uses alpha particles, which are highly effective at damaging cancer cells while causing minimal harm to surrounding healthy tissue. This targeted approach is expected to result in fewer side effects compared to other types of radiation therapy. This Phase 1 study consists of two main parts: dose escalation and dose expansion. In the first part, researchers will test different doses of AB001 to find the safest and most effective dose. In the second part, the selected dose will be further evaluated to refine the treatment schedule and gather more data on its effectiveness and safety. The study aims to provide early data on the anti-tumour activity of AB001 and determine the best dose and treatment schedule for future trials. Researchers hope that AB001 will offer a new and effective treatment option for patients with advanced prostate cancer.
Phase 1
Recruiting
BAMF Health (+3 Sites)Margaret YuARTBIO Inc.
Image of Icahn School of Medicine at Mount Sinai in New York, United States.

Darolutamide + Pembrolizumab + Lupron for Prostate Cancer

18+
Male
New York, NY
This is a single-arm, phase II study of neoadjuvant combination therapy of Androgen Deprivation Therapy (ADT), \[Gonadotropin-Releasing Hormone (GnRH) agonist Leuprolide\], androgen receptor (AR)-antagonist Darolutamide and Pembrolizumab in a stratified high-risk localized prostate cancer cohort, followed by adjuvant treatment with Pembrolizumab (12 cycles) post-radical prostatectomy (RP). Patients with National Comprehensive Cancer Network (NCCN) high-risk non-metastatic prostate cancer (localized or locally advanced) (defined as Gleason ≥8, disease stage \>=cT3a, or PSA l \>20 ng/mL) will be risk-stratified at a biopsy using Decipher, a commercial standard-of-care diagnostic assay. Patients satisfying all three criteria of high-risk genomic characteristics listed below as per the Decipher grid results will be enrolled in the study: 1. Decipher Genomic classifier, GC\>0.6 2. AR activity score/AR-output gene signature (ARoS)\>11.0 3. High Luminal B score/ PAM50 subtype signature
Phase 2
Waitlist Available
Icahn School of Medicine at Mount SinaiAshutosh K Tewari, MDMerck Sharp & Dohme LLC
Have you considered Zytiga clinical trials? We made a collection of clinical trials featuring Zytiga, we think they might fit your search criteria.Go to Trials
Image of Excel Diagnostics & Nuclear Oncology Center in Houston, United States.

Lutetium-177-PSMA-617 for Prostate Cancer

18+
Male
Houston, TX
The purpose of this study is to evaluate the safety and tolerability of Lutetium-177-PSMA-617 (PLUVICTO) in patients with metastatic castration-resistant prostate cancer (mCRPC) and extensive bone metastases, which appear as a "super scan" pattern on a bone scan. Pluvicto is FDA-approved, but patients with super scan bone scans were previously excluded from the VISION clinical trial, leaving a knowledge gap. The study will enroll up to 30 men with metastatic castration-resistant prostate cancer, with an initial dosing approach that differs from the standard dose. The safety and tolerability of PLUVICTO will be evaluated in this study, with a focus on identifying the optimal dose for this population. This study addresses an important gap in understanding how Pluvicto performs in mCRPC patients with super scan findings.
Phase 2
Recruiting
Excel Diagnostics & Nuclear Oncology CenterEbrahim S. Delpassand, M.D. Chairman & Medical Director, MD., Nuclear Medicine
Image of CHU de Québec-Université Laval in Quebec, Canada.

177Lu-PSMA-617 for Prostate Cancer

18+
Male
Quebec, Canada
The goal of this clinical trial is to assess if a personalized regime of 177Lu-PSMA-617 (Lutetium Lu 177 vipivotide tetraxetan, also known as Pluvicto) is feasible and safe in a population of patients with metastatic castrate-resistant prostate cancer (mCRPC). The main questions it aims to answer are: 1. Can the administered activity (cumulative or per-cycle) be increased in a majority of participants? 2. What is the incidence of some specific adverse reactions during the treatment? Researchers will compare participants receiving a personalized regime to participants receiving the standard fixed-activity regime of 177Lu-PSMA-617 to see if the activity can be safely increased through personalization based on renal dosimetry (i.e. the measure of how much radiation is actually delivered to the kidney). Participants will receive up to 6 treatments of 177Lu-PSMA-617 every 6 weeks and be regularly evaluated with imaging and laboratory tests, as well as with questionnaires.
Phase 1
Recruiting
CHU de Québec-Université Laval (+1 Sites)Jean-Mathieu Beauregard, MDNovartis
Image of Urology Cancer Center PC in Omaha, United States.

Lutetium (177Lu) Vipivotide Tetraxetan + ARPI for Prostate Cancer

18 - 100
Male
Omaha, NE
The purpose of this study is to assess whether the combination of AAA617 (administered for 6 cycles at a dose of 7.4 GBq (200 mCi) +/- 10%) and ARPI improves radiographic progression-free survival (rPFS) or time to death compared to AAA617 alone in PSMA-positive mCRPC patients who were previously treated and progressed on ARPI in the biochemical recurrence (BCR)-non metastatic hormone sensitive prostate cancer (mHSPC), mHSPC, or non-metastatic Castration Resistant Prostate Cancer (nmCRPC) setting and have not previously received a taxane-containing regimen in the castrate resistant prostate cancer (CRPC) setting.
Phase 2
Recruiting
Urology Cancer Center PC (+13 Sites)Novartis PharmaceuticalsNovartis Pharmaceuticals
Have you considered Zytiga clinical trials? We made a collection of clinical trials featuring Zytiga, we think they might fit your search criteria.Go to Trials
Image of University of Chicago Medicine, High-Risk and Advanced Prostate Cancer Clinic in Chicago, United States.

FK-PC101 for Prostate Cancer

Any Age
Male
Chicago, IL
The goal of this clinical trial is to learn if the vaccine FK-PC101 works to delay or prevent the return of prostate cancer in men who have had surgery to remove their prostate cancer. It will also learn about the safety of FK-PC101. The main questions it aims to answer are: Does FK-PC101 delay or prevent the return of prostate cancer following surgery? What medical problems do participants (subjects) have when taking FK-PC101? Researchers will compare FK-PC101 to current treatment practice to see if FK-PC101 works to prevent or delay the return of prostate cancer following surgery to remove the prostate cancer tumor. Subjects will: Have a sample of the prostate cancer tissue collected at the time of surgery to remove this tissue from the body. This tissue will then be used to create a personalized vaccine that is specific to your prostate cancer. If randomly selected to receive the vaccine, subjects will receive the vaccine up to 7 times over a 6-month period. In addition to the treatment visits for those randomized to receive FK-PC101, there will be up to 4 follow up visits to the clinic over a 22-month (nearly 2 year) period. For subjects randomized to receive current treatment practice, they will be asked to attend up to 8 visits over 22 months to track if there is any detectable cancer. Should their prostate cancer return within a year following surgery, they will be eligible to receive FK-PC101, which already had been produced and thus no additional tumor tissue would need to be obtained. Subjects in both study arms will have regular blood tests and scans to test whether their prostate cancer has returned.
Phase 2
Recruiting
University of Chicago Medicine, High-Risk and Advanced Prostate Cancer Clinic (+3 Sites)Fernando Kreutz, MD PhDCellvax Therapeutics Inc
Image of Baptist M&S Imaging (Medical Center) in San Antonio, United States.

PF-06821497 + Enzalutamide for Prostate Cancer

18+
Male
San Antonio, TX
Pfizer MEVPRO-1 (C2321014) is a randomized, open-label, multi-center clinical trial evaluating whether combining the study medicine (PF-06821497) with enzalutamide is safe and effective compared to physician's choice of either second-line androgen receptor (AR) directed therapy with enzalutamide or docetaxel (chemotherapy) for treating metastatic castration-resistant prostate cancer (mCRPC) after progression on prior abiraterone acetate treatment. The primary objective of this clinical trial is to assess the radiographic progression free survival (rPFS) of the combination of PF-06821497 plus enzalutamide versus physician's choice of enzalutamide or docetaxel.
Phase 3
Recruiting
Baptist M&S Imaging (Medical Center) (+28 Sites)Pfizer CT.gov Call CenterPfizer
Have you considered Zytiga clinical trials? We made a collection of clinical trials featuring Zytiga, we think they might fit your search criteria.Go to Trials
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security